Home / OKUR : NASDAQ

AI Analysis Fundamentals Valuation Video Analysis News Similar

AI Analysis

How does OKUR make money? Does OKUR have pricing power? What's the Earnings Whisper? Will OKUR profit more as the business scales? What is OKUR's management track record? Is OKUR's current price justified?

OnKure Therapeutics, Inc.

$3.1 +$0.14 (+4.73%)

NASDAQ · 11 Sep 2026 20:00 UTC

Previous Close

$3.27

Day Range

$3.07$3.33

Year Range

$2.23$5.38

Market Cap

125.54M

AVG Volume

256.85K

Trailing/Forward PE

-0.89/-

PEG ratio

0.05

Dividend Yield

Next Earnings Date

2026-11-05

Primary Exchange

NASDAQ

Net Income (USD)

OKUR Net Income (USD) by year
Period	Net Income (USD)
2025	-59.52M
2024	-62.56M
2023	-17.54M

Operating Income (USD)

OKUR Operating Income (USD) by year
Period	Operating Income (USD)
2025	-62.95M
2024	-62.64M
2023	-16.97M

EBITDA (USD)

OKUR EBITDA (USD) by year
Period	EBITDA (USD)
2025	-58.68M
2024	-58.19M
2023	-16.77M

Cash Flows (USD)

OKUR Cash Flows (USD) by year
Period	Cash Flows (USD)
2025	-51.87M
2024	-48.87M
2023	-25.17M

EPS (USD)

OKUR EPS (USD) by year
Period	EPS (USD)
2025	-4.41
2024	-4.69
2023	-1.31

Expenses (USD)

OKUR Expenses (USD) by year
Period	Expenses (USD)
2025	63M
2024	62.72M
2023	17.07M

Cash & Debt (USD)

OKUR Cash & Debt (USD) by year
Period	Cash & Debt (USD)
2025	59.05M
2024	110.76M
2023	29.88M

Debt ratios

OKUR Debt ratios by year
Period	Debt ratios
2025	9.97
2024	10.52
2023	4.1

Return on Capital

OKUR Return on Capital by year
Period	Return on Capital
2025	-105.93%
2024	-60.25%
2023	17.22%

Shares Outstanding

OKUR Shares Outstanding by year
Period	Shares Outstanding
2025	13.52M
2024	13.34M
2023	13.34M

Book Value Per Share (USD)

OKUR Book Value Per Share (USD) by year
Period	Book Value Per Share (USD)
2025	4.16
2024	7.78
2023	-7.63

Total Assets (USD)

OKUR Total Assets (USD) by year
Period	Total Assets (USD)
2025	62.12M
2024	114.91M
2023	35.73M

Employee Count

OKUR Employee Count by year
Period	Employee Count
2025	45
2024	46
2023	8
2022	36
2021	20

Free Cash Flow Yield

OKUR Free Cash Flow Yield by year
Period	Free Cash Flow Yield
Sep 26	-30.96%
Sep 26	-26.81%
Aug 26	-25.32%
Aug 26	-24.36%
Aug 26	-24.05%
Aug 26	-23.18%
Jul 26	-97.24%
Jul 26	-90.16%
Jul 26	-88.44%
Jul 26	-86.79%
Jul 26	-81.1%
Jun 26	-82.54%
Jun 26	-82.91%
Jun 26	-88.44%
Jun 26	-88.65%
May 26	-88.44%
May 26	-88.23%
May 26	-117.55%
May 26	-95%
May 26	-81.14%
Apr 26	-79.96%
Apr 26	-76.76%
Apr 26	-89.26%
Apr 26	-89.46%
Mar 26	-96.19%
Mar 26	-91.6%
Mar 26	-101.53%
Mar 26	-149.06%
Feb 26	-167.76%
Feb 26	-174.86%
Feb 26	-187.87%
Feb 26	-181.86%
Jan 26	-172.21%
Jan 26	-155.17%
Jan 26	-151.55%
Jan 26	-144.79%
Jan 26	-153.6%
Dec 25	-162.37%
Dec 25	-151.04%
Dec 25	-148.09%
Dec 25	-148.58%
Nov 25	-151.04%
Nov 25	-176.22%
Nov 25	-145.25%
Nov 25	-154.64%
Oct 25	-128.95%
Oct 25	-131.67%
Oct 25	-157.25%
Oct 25	-143.33%
Oct 25	-161.31%
Sep 25	-174.16%
Sep 25	-170.09%
Sep 25	-178.43%
Sep 25	-158.96%
Aug 25	-158.96%
Aug 25	-154.47%
Aug 25	-172.78%
Aug 25	-190.79%
Aug 25	-176.92%
Jul 25	-168.49%
Jul 25	-167.05%
Jul 25	-155.69%
Jul 25	-163.54%
Jun 25	-162.17%
Jun 25	-164.23%
Jun 25	-146.87%
Jun 25	-135.15%
May 25	-153.84%
May 25	-181.03%
May 25	-194.61%
May 25	-202.72%
May 25	-146.53%
Apr 25	-140.89%
Apr 25	-126.75%
Apr 25	-124.18%
Apr 25	-117.04%
Mar 25	-82.13%
Mar 25	-72.54%
Mar 25	-79.46%
Mar 25	-72.97%
Feb 25	-27.31%
Feb 25	-25.36%
Feb 25	-24.12%
Feb 25	-23.66%
Jan 25	-22.51%
Jan 25	-24.46%
Jan 25	-23.91%
Jan 25	-18.63%
Jan 25	-15.43%
Dec 24	-16.97%
Dec 24	-16.52%
Dec 24	-14.04%
Dec 24	-9.78%
Nov 24	-8.98%
Nov 24	-12.81%
Nov 24	-12%
Nov 24	-11.33%
Nov 24	-12.23%
Oct 24	-11.7%
Oct 24	-10.76%

Price to Book

OKUR Price to Book by year
Period	Price to Book
Sep 26	0.9
Sep 26	1.04
Aug 26	1.1
Aug 26	1.14
Aug 26	1.16
Aug 26	1.2
Jul 26	0.28
Jul 26	0.31
Jul 26	0.31
Jul 26	0.32
Jul 26	0.34
Jun 26	0.33
Jun 26	0.33
Jun 26	0.31
Jun 26	0.31
May 26	0.31
May 26	0.31
May 26	0.23
May 26	0.29
May 26	1.14
Apr 26	1.15
Apr 26	1.2
Apr 26	1.03
Apr 26	1.03
Mar 26	0.96
Mar 26	1.01
Mar 26	0.91
Mar 26	0.62
Feb 26	0.55
Feb 26	0.53
Feb 26	0.49
Feb 26	0.51
Jan 26	0.54
Jan 26	0.6
Jan 26	0.61
Jan 26	0.64
Jan 26	0.6
Dec 25	0.57
Dec 25	0.61
Dec 25	0.62
Dec 25	0.62
Nov 25	0.61
Nov 25	0.52
Nov 25	0.64
Nov 25	0.6
Oct 25	0.59
Oct 25	0.57
Oct 25	0.48
Oct 25	0.53
Oct 25	0.47
Sep 25	0.43
Sep 25	0.44
Sep 25	0.42
Sep 25	0.48
Aug 25	0.48
Aug 25	0.49
Aug 25	0.44
Aug 25	0.3
Aug 25	0.33
Jul 25	0.34
Jul 25	0.35
Jul 25	0.37
Jul 25	0.35
Jun 25	0.36
Jun 25	0.35
Jun 25	0.39
Jun 25	0.43
May 25	0.37
May 25	0.32
May 25	0.3
May 25	0.28
May 25	0.32
Apr 25	0.33
Apr 25	0.37
Apr 25	0.38
Apr 25	0.4
Mar 25	0.57
Mar 25	0.65
Mar 25	0.59
Mar 25	0.64
Feb 25	0.91
Feb 25	0.98
Feb 25	1.03
Feb 25	1.05
Jan 25	1.11
Jan 25	1.02
Jan 25	1.04
Jan 25	1.34
Jan 25	1.62
Dec 24	1.47
Dec 24	1.51
Dec 24	1.78
Dec 24	2.55
Nov 24	2.78
Feb 24	1.87
Feb 24	1.91
Feb 24	2.02
Feb 24	1.85
Jan 24	1.91
Jan 24	1.87

No video analysis for this stock yet. Request one from our team.

News: OKUR

globenewswire.com · 31 Aug 2026

OnKure Therapeutics to Participate in the Morgan Stanley Global Healthcare Conference

BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines, today announced that senior management will participate in the upcoming Morgan Stanley 24th Annual Global Healthcare Conference being held in New York on September 14 – 16, 2026.

globenewswire.com · 4 Aug 2026

OnKure Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-345 in breast cancer and OKI-355 in vascular anomalies, with IND submissions planned for 1H 2027

marketbeat.com · 15 Jul 2026

OnKure Therapeutics Spotlights Allosteric PI3Kα Drugs as 2027 IND Targets Near

OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mutant-selective PI3Kα inhibitors, emphasizing allosteric inhibition as a potential way to improve efficacy and tolerability in cancer and vascular anomalies.

globenewswire.com · 2 Jul 2026

OnKure Therapeutics to Host Virtual KOL Event to Discuss PI3Kα Inhibitor Medicines: Selectivity Matters & Pan-Mutant Allosteric Inhibition Delivers, on July 15, 2026

BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinical-stage biopharmaceutical company focused on developing novel precision medicines, today announced that it will host a virtual key opinion leader (KOL) event on Wednesday, July 15, 2026 at 11:00 AM ET featuring Benjamin F. Cravatt, PhD (The Scripps Research Institute) and Robert Abraham, PhD (Engine Biosciences). They will join company management to discuss the significance of PI3Kα selectivity and the Company's structure-based drug design approach for discovering allosteric pan-mutant PI3Kα inhibitors. To register, click here.